Like most on this board, I am stunned that with 2 drugs

New Post Public Reply Private Reply Replies (1) Message Board
petemantx
790
Like most on this board, I am stunned that with 2 drugs having the potential of Kevetrin and Brilacidin that we are still sitting in the shitter as to share price. I have utmost belief in the science, but I have absolutely no faith whatsoever in the bureaucratic BS of the Americn medical system, the clinical trial system, the involvement of the federal government in medical research, the FDA, CDC, and the AMA.

I believe Brilacidin did not fail the recent Covid trial but that the setup of the clinical trial (and IPIX mgt accepting the setup of the trial) as failing Brilacidin and the American public in bringing this drug to market. IMO the medical community is culpable for tens if not hundreds of thousands of deaths due to Covid worldwide. I base this on the mysteriously fast approval of very questionable vaccines, the stonewalling of new therapeutics and the handling of therapeutics in their entirety in regards to the Covid situation, the rigidity of the clinical trial program that causes undue delay in advancing promising treatments, the expected payola to many, many people in the whole medical bureaucratic system, and the lack of physicians demanding a change in the current monolithic system.

Do I sound pissed off? I hope so because I am irate over the whole situation.

Let's look at the history of Brilacidin to make my point. It was developed nearly 20 years ago (20 YEARS!!!!!!!), 2002, as that is when Polymedix was founded. Yet with all the history of research of its wonderful properties here we sit with no commercial applications for it yet. The government needs more testing of it even though the DeGrado Lab at UCSF has been researching defensin mimetics since 2013 and Brilacidin is considered the foundational drug of this new arm of medicine. Anybody else see a major problem here? It was shown to be superior to Daptomycin as a new age antibiotic that was pretty much immune to bacterial resistance and yet it has been shelved for many, many, many years due to lack of funds to run a phase 3 trial even though we keep hearing about the calamity of superbugs developing that can overcome all current antibiotics. I say the 3000 patient trial number the FDA is total BS and the lack of funds is a disgrace when the govt just gave Billions upon Billions to BPs to try and revamp their current load of outdated POS drugs to work against Covid. Typical government waste (or payobla) throwing money right down the crap hole. The invitro lab results of B against Covid were spectacular yet the trial was run at a far reduced dosage to that dosage IPIX wanted it run (at least that is what I have been led to believe). As to the trial, when they stopped it after 25% patients were enrolled to evaluate going from 3 to 5 days of dosings, they had to have seen the poor results to date but the committee of dolts didn't suggest upping the dosage in a possible new arm to see if that was the problem? No, they let it run out so that now to find if that was the problem a new trial would have to be run and thats another years delay, but hey, its only people still dying so what's the problem, right???

As for mgt, if the dosage was taken down by the FDA why didn't they also demand that the results be reduced drastically since they had to expect the results would be far less impressive than what the full dosage would have returned. Makes me wonder what the hell is Harkness doing as isn't she the trial person? After Prurisol and Brilacidin trials, I'd sack her ass in a heartbeat.

Bottom line - It seems quite evident that for IPIX to succeed and our drugs have any chance of seeing the light of day that we will be required to have a "favored" partner by the medical/government establishment. Another way of saying "greasing the right palms" IMO. If Leo hasn't figured this out yet maybe time to get rid of him. He has suffered nothing with his pay still quite robust (and has been all these last 10 years or so) and his "need for speed" is lacking IMO

No way in hell I believe it has taken this long for secondary/CU data to be collated as the data was locked in early Nov. I am hoping some major developments or even minor developments are revealed later this month but I am dreading all we hear is more time needed for further study and months to go before we hear of any grant money or some type of governmental money coming in.



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 7

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 5

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
2026 Buy-Side Index Reveals State Market Variance

Updated Category News Views 6

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 11

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 5

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Americas Cardroom's Poker Series Hits $7.2M Haul

Updated Category News Views 5

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Lick the Plate Hits 2,000 Shows with Clown Band

Updated Category News Views 5

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Continue Reading
NYSE Reflects on 9/11: Honoring Lives and Legacy

Updated Category News Views 6

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Continue Reading

Top 5 Most Recently Viewed Articles

Investor Concerns on Grab Holdings’ Economic Positioning

Updated Category News Views 238

Understanding Grab Holdings in Today's Market Adam Khoo, a notable entrepreneur from Southeast Asia, has recently raised some eyebrow-raising comments regarding the investment potential of Grab Holdings Ltd. (NASDAQ: GRAB). With the company’s stock climbing 8.16%, reaching $5.30, and reflecting a 51.86% increase over the past year, many investors are questioning the...

Continue Reading
Explore JOYIN's Innovative Toy Brands at Spielwarenmesse 2026

Updated Category News Views 142

Discover JOYIN's Presence at Spielwarenmesse 2026 At the renowned Spielwarenmesse 2026, JOYIN is set to unveil its impressive array of toy solutions tailored for retailers and distributors. With a focus on quality and innovation, JOYIN's participation highlights their commitment to serving the global toy market effectively. Introducing JOVA: The Core Toy Brand Platform...

Continue Reading
Celebrating John P. Lynes: Neurosurgeon Excellence Recognized

Updated Category News Views 229

John P. Lynes Achieves Pinnacle Lifetime Membership Recently recognized in The Inner Circle, John P. Lynes, MD, has been awarded the esteemed Pinnacle Lifetime Membership for his outstanding contributions to the field of Brain and Spine Surgery. Professional Background and Specialization Dr. Lynes is a distinguished neurosurgeon with expertise in treating tumors of the...

Continue Reading
Viral Nation Unveils Enhanced Version of Secure Solution

Updated Category News Views 364

Viral Nation Unveils Enhanced Version of Secure Solution Viral Nation, a prominent global social media marketing and creator agency, is excited to announce a significant update to its innovative AI-powered brand reputation solution, Secure. This update aims to help brands identify brand safety blind spots effectively while ensuring they make well-informed influencer...

Continue Reading
Tripadvisor, Inc. Reports Impressive Q4 and Full Year Earnings

Updated Category News Views 222

Tripadvisor, Inc. Earnings Overview Tripadvisor, Inc. has recently released its earnings report for the fourth quarter and the entirety of 2024, showcasing significant progress and growth. As a leading travel company, Tripadvisor operates a versatile portfolio that connects travelers to inspiring experiences. Fourth Quarter Highlights The fourth quarter results reflect...

Continue Reading